No evidence for cardiotoxicity of miltefosine - Reply
- PMID: 35667981
- PMCID: PMC9263635
- DOI: 10.1016/j.abd.2022.03.001
No evidence for cardiotoxicity of miltefosine - Reply
Comment on
-
No evidence for cardiotoxicity of miltefosine.An Bras Dermatol. 2022 Jul-Aug;97(4):548-549. doi: 10.1016/j.abd.2022.03.002. Epub 2022 May 30. An Bras Dermatol. 2022. PMID: 35654652 Free PMC article. No abstract available.
References
-
- Sundar S., Jha T., Thakur C., Engel J., Sindermann H., Fischer C., et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347:1739–1746. - PubMed
-
- Motulsky H. 4th ed. Oxford University Press; USA: 2018. Intuitive biostatistics: a nonmathematical guide to statistical thinking.
-
- Dorlo T.P., Balasegaram M., Beijnen J.H., de Vries PJ. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012;67:2576–2597. - PubMed
-
- Martins S.S., Barroso D.H., Rodrigues B.C., da Motta JDOC, Freire G.S.M., Pereira Lida, et al. A pilot randomized clinical trial: oral miltefosine and pentavalent antimonials associated with pentoxifylline for the treatment of American tegumentary leishmaniasis. Front Cell Infect Microbiol. 2021;11 - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources